Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Immunologic Adjuvants. Found 5 abstracts

Alvarez P, Jensen LE. Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner. Mediators of inflammation. 2016 Jan;2016:6756138.   PMCID: PMC5183767
Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42.
McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 2001 May 15;166(10):6112-7.
Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001 Oct;7(10):3012-24.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt). 2000 May;14(5):719-29; discussion 729-31, 734, 737.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Immunologic Adjuvants

Immunologic Adjuvants Human Female therapeutic use metabolism Male adverse effects chemically induced US Gov't Support-PHS immunology drug therapy Skin Non-US Gov't Support Cancer Vaccines pathology Antineoplastic Agents administration & dosage Mice Neutrophil Infiltration Photochemotherapy Body Temperature Kinetics Saponins Bladder Neoplasms Antibody Binding Sites Immunoglobulin Variable Region Antibody-Dependent Cell Cytotoxicity prevention & control HLA-A2 Antigen Animal Disease Models Pain Psoriasis Anticarcinogenic Agents IgG Receptors Antibody Specificity Follow-Up Studies Cytokines Neutrophils Thiotepa Time Factors Interleukin-1 Type I Receptors Intracellular Fluid therapy Melanoma T-Lymphocyte Epitopes analogs & derivatives Neoplasm Antigens Headache Treatment Outcome Neoplasm Proteins drug effects cytology Epirubicin Survival Analysis Combined Modality Therapy Calcium Signaling CD4-Positive T-Lymphocytes Th1 Cells Amino Acid Sequence Middle Age Intravesical Administration Biological Therapy Membrane Glycoproteins Inbred C57BL Mice Molecular Sequence Data Cell Division Photosensitizing Agents Antineoplastic Antibiotics Lymph Nodes Inflammation Immunologic Cytotoxicity Tests Interferon Type II Neoplasm Drug Resistance Cultured Tumor Cells Residual Neoplasm Bispecific Antibodies Ovarian Neoplasms Aminoquinolines Skin Tests Interferons Antineoplastic Combined Chemotherapy Protocols Skin Diseases Cytotoxic T-Lymphocytes Delayed Hypersensitivity Interleukin-1 Doxorubicin Pain Measurement Mycobacterium bovis toxicity Mitomycin Tetanus Toxoid Transitional Cell Carcinoma erbB-2 Receptor Peptide Fragments secretion Cell Line Sex Factors Neoplasm Staging Gene Therapy
Last updated on Monday, May 04, 2020